Affymax (OTCMKTS:AFFY) Stock Passes Above 200 Day Moving Average – Time to Sell?

Shares of Affymax Inc. (OTCMKTS:AFFY – Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.0016. Affymax shares last traded at $0.0016, with a volume of 750 shares trading hands.

Affymax Stock Down 56.2%

Get Affymax alerts:

About Affymax

(Get Free Report)

Affymax, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare and underserved diseases. The company leverages its proprietary TransCon® drug delivery platform to create prodrugs that offer sustained, predictable release of active pharmaceutical ingredients. Affymax’s research efforts concentrate on endocrinology and nephrology indications, seeking to address conditions that currently have limited treatment options.

Among its lead product candidates, Affymax is advancing TransCon® PTH for the treatment of hypoparathyroidism and TransCon® Growth Hormone (TransCon® GH) for pediatric growth hormone deficiency.

See Also

• Five stocks we like better than Affymax
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
• Legacy Jet Builders Stall While Embraer Accelerates to New Highs

Receive News & Ratings for Affymax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymax and related companies with MarketBeat.com's FREE daily email newsletter.